Malignant melanoma - Interferon alpha: an important option in the therapy of high-risk patients

被引：0
作者：
不详
机构：
来源：
HAUTARZT | 2005年 / 56卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：1190 / 1190
页数：1
相关论文
共 50 条
  • [21] A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma
    Suarez-Kelly, Lorena P.
    Levine, Kala M.
    Olencki, Thomas E.
    del Campo, Sara E. Martin
    Streacker, Elizabeth A.
    Brooks, Taylor R.
    Karpa, Volodymyr I.
    Markowitz, Joseph
    Bingman, Anissa K.
    Geyer, Susan M.
    Kendra, Kari L.
    Carson, William E.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (04) : 619 - 629
  • [22] The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy (vol 32, 440, 2015)
    Akman, Tulay
    Oztop, Ilhan
    Baskin, Yasemin
    Akbarpour, Mahdi
    Unal, Olcun Umit
    Oflazoglu, Utku
    Ellidokuz, Hulya
    Lebe, Banu
    MEDICAL ONCOLOGY, 2015, 32 (03)
  • [23] Systemic adjuvant therapy for patients with high-risk melanoma
    Tsai, Kenneth Y.
    ARCHIVES OF DERMATOLOGY, 2007, 143 (06) : 779 - 782
  • [24] Excision margins in high-risk malignant melanoma
    Thomas, JM
    Newton-Bishop, J
    A'Hern, R
    Coombes, G
    Timmons, M
    Evans, J
    Cook, M
    Theaker, J
    Fallowfield, M
    O'Neill, T
    Ruka, W
    Bliss, JM
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (08) : 757 - 766
  • [25] Excision margins in high-risk malignant melanoma
    Hurt, MA
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (22) : 2305 - 2305
  • [26] ADJUVANT IMMUNOTHERAPY - TREATMENT OF HIGH-RISK PATIENTS WITH MALIGNANT-MELANOMA
    THOMAS, JH
    MALONEY, BE
    JEWELL, WR
    JOURNAL OF THE KANSAS MEDICAL SOCIETY, 1978, 79 (03): : 107 - 110
  • [27] Adjuvant Interferon-Alpha Treatment for High-Risk Melanoma Patients: A Single Tertiary Care Center Experience
    Allen, K.
    Graham, N.
    Godbout, L.
    Young, V
    Verma, S.
    Song, X.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 61 - 61
  • [28] Influence of immunotherapy with pegylated interferon-alpha on platelet monoamine oxidase activity in high-risk melanoma patients
    Fekkes, D
    van Gool, AR
    van Ojik, HH
    Bannink, M
    Mulder, PGH
    Kruit, WHJ
    Eggermont, AMM
    Stoter, G
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S206 - S207
  • [29] Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
    Christofyllakis, Konstantinos
    Pfoehler, Claudia
    Bewarder, Moritz
    Mueller, Cornelia S. L.
    Thurner, Lorenz
    Rixecker, Torben
    Vogt, Thomas
    Stilgenbauer, Stephan
    Yordanova, Krista
    Kaddu-Mulindwa, Dominic
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [30] Adjuvant Therapy for High-Risk Melanoma
    Tarhini, Ahmad A.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2014, 10 (05) : 4 - 13
12345